CD19 and plasma cell myeloma: These promising results were the basis for the ongoing phase I clinical trial in relapsed/refractory non-Hodgkin lymphoma and multiple myeloma patients as monotherapy or in combination with rituximab or daratumumab (NCT04136756), and for the recently posted phase Ib clinical trial in relapsed or refractory large B-cell lymphoma in combination with CD19-targeted CART T cell immunotherapy (NCT05359211) [41].